Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: Is less really more?

Journal of Hypertension

Volumn 28, Issue 7, 2010, Pages 1384-1389

  Budzyn, Klaudia ^a   Sobey, Christopher G ^a   Drummond, Grant R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ENALAPRIL; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TELMISARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTERIOLE; BRAIN ARTERY; BRAIN ISCHEMIA; BRAIN PROTECTION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; MICROVASCULATURE; MONOTHERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 77954354763     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833c03fe     Document Type: Note

References (24)

1. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371:1513-1518.
2. Heistad DD, Baumbach GL. Cerebral vascular changes during chronic hypertension:good guys and bad guys. JHypertens Suppl 1992; 10:S71-S75.
3. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab 2008; 7:476-484.
4. Dupuis F, Vincent J-M, Liminana P, Chillon J-M, Capdeville-Atkinson C, Atkinson J. Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat. J Hypertens 2010; 28:1566-1573.
5. Dupuis F, Atkinson J, Liminana P, Chillon JM. Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats. J Hypertens 2005; 23:1061-1066.
6. Brait VH, Jackman KA, Walduck AK, Selemidis S, Diep H, Mast AE, et al. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab 2010. [Epub ahead of print]
7. Jackman KA, Miller AA, Drummond GR, Sobey CG. Importance of NOX1 for angiotensin II-induced cerebrovascular superoxide production and cortical infarct volume following ischemic stroke. Brain Res 2009; 1286:215-220.
8. Hamai M, Iwai M, Ide A, Tomochika H, Tomono Y, Mogi M, Horiuchi M. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology 2006; 51:822-828.
9. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771. (Pubitemid 37093916)
10. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174-1183.
11. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
12. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50:439-465.
13. Touyz RM. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003; 5:155-164.
14. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 2008; 120:292-316.
15. Widdop RE, Vinh A, Henrion D, Jones ES. Vascular angiotensin AT2 receptors in hypertension and ageing. Clin Exp Pharmacol Physiol 2008; 35:386-390.
16. Steckelings UM, Kaschina E, Unger T. The AT2 receptor: a matter of love and hate. Peptides 2005; 26:1401-1409.
17. Sobey CG, Heistad DD, Faraci FM. Mechanisms of bradykinin-induced cerebral vasodilatation in rats. Evidence that reactive oxygen species activate K\+ channels. Stroke 1997; 28:2290-2294; discussion 2295.
18. Vinh A, Widdop RE, Drummond GR, Gaspari TA. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 2008; 77:178-187.
19. Yayama K, Okamoto H. Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 2008; 8:312-318.
20. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the nonpeptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 2010; 159:709-716.
21. Miller AA, Drummond GR, Schmidt HH, Sobey CG. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res 2005; 97:1055-1062.
22. Paravicini TM, Chrissobolis S, Drummond GR, Sobey CG. Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke 2004; 35:584-589.
23. Naveri L. The role of angiotensin receptor subtypes in cerebrovascular regulation in the rat. Acta Physiol Scand Suppl 1995; 630:1-48.
24. Zhou J, Pavel J, Macova M, Yu ZX, Imboden H, Ge L, et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 2006; 37:1271-1276.